UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-A/A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Vanda Pharmaceuticals Inc.

Delaware		03-0491827
(State of incorporation or organization)		(I.R.S. Employer
		Identification no.)

9605 Medical Center Drive, Suite 300, Rockville,
Maryland 20850		20850
(Address of principal executive offices)		(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class		Name of each exchange on which
to be so registered		each class is to be registered
Rights to Purchase Series A Junior Participating
Preferred Stock		The NASDAQ Global Market

		If this form relates to the registration of		If this form relates to the registration of
		a class of securities pursuant to Section		a class of securities pursuant to Section
		12(b) of the Exchange Act and is		12(g) of the Exchange Act and is
		effective pursuant to General		effective pursuant to General
		Instruction A.(c), please check the		Instruction A.(d), please check the
		following box. þ		following box. o

		Securities Act registration statement file number to which this form relates:		Not applicable
				(If Applicable)

Securities to be registered pursuant to Section 12(g) of the Act: None

 

 

EXPLANATORY NOTE

     This Form 8-A/A is being filed solely to update the Form 8-A to include the terms provided in Amendment to Rights Agreement dated December 22, 2009 to Rights Agreement dated as of September 25, 2008 (the “Amendment”), between Vanda Pharmaceuticals Inc. (the “Company”) and American Stock Transfer & Trust Company, LLC, as Rights Agent (the “Rights Agent”). A copy of the Amendment is included as Exhibit 4 to this registration statement and is incorporated herein by reference.

THE REGISTRATION STATEMENT ON FORM 8-A DATED SEPTEMBER 25, 2008, AND RELATING TO THE RIGHTS TO PURCHASE SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF THE COMPANY, IS HEREBY AMENDED AS FOLLOWS:

Item 1. Description of Registrant’s Securities to be Registered.

THE FIRST PARAGRAPH IN ITEM 1 IS HEREBY AMENDED AND RESTATED AS FOLLOWS:

          On September 25, 2008, based on, inter alia, the recommendation of the Nominating and Governance Committee of Directors, the Board of Directors of Vanda Pharmaceuticals Inc. (the “Company”) declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of common stock, par value $0.001 per share, of the Company (the “Common Stock”). The dividend is payable on October 25, 2008 to the stockholders of record on October 6, 2008 (the “Record Date”). Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value $0.001 per share, of the Company (the “Preferred Stock”) at a price of $66.00 per one one-thousandth of a share of Preferred Stock (the “Purchase Price”), subject to adjustment. The description and terms of the Rights are set forth in a Rights Agreement dated as of September 25, 2008, as the same may be amended from time to time (the “Rights Agreement”), between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent (the “Rights Agent”).

Item 2. Exhibits.

          4. Amendment to Rights Agreement, dated as of December 22, 2009, between Vanda Pharmaceuticals Inc. and American Stock Transfer & Trust Company, LLC, as Rights Agent.

SIGNATURE

          Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

		VANDA PHARMACEUTICALS INC.
Date: December 22, 2009		By:		/s/ Stephanie R. Irish
		Name:		Stephanie R. Irish
		Title:		Acting Chief Financial Officer and Treasurer